141 related articles for article (PubMed ID: 19926672)
1. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.
Hassan B; Maxwell JR; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
Rheumatology (Oxford); 2010 Jan; 49(1):43-7. PubMed ID: 19926672
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients.
Coulthard LR; Taylor JC; Eyre S; ; Robinson JI; Wilson AG; Isaacs JD; Hyrich K; Emery P; Barton A; Barrett JH; Morgan AW; McDermott MF
Ann Rheum Dis; 2011 Jan; 70(1):98-103. PubMed ID: 20805296
[TBL] [Abstract][Full Text] [Related]
3. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
[TBL] [Abstract][Full Text] [Related]
4. Plasma soluble IL-6 receptor concentration in rheumatoid arthritis: associations with the rs8192284 IL6R polymorphism and with disease activity.
Rodríguez-Rodríguez L; Lamas JR; Varadé J; López-Romero P; Tornero-Esteban P; Abasolo L; de la Concha EG; Jover JA; Urcelay E; Fernández-Gutiérrez B
Rheumatol Int; 2011 Mar; 31(3):409-13. PubMed ID: 20661738
[TBL] [Abstract][Full Text] [Related]
5. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
[TBL] [Abstract][Full Text] [Related]
6. Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort.
Plant D; Ibrahim I; Lunt M; Eyre S; Flynn E; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
Arthritis Res Ther; 2012 Oct; 14(5):R214. PubMed ID: 23039402
[TBL] [Abstract][Full Text] [Related]
7. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
[TBL] [Abstract][Full Text] [Related]
8. Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment.
Mathews RJ; Robinson JI; Battellino M; Wong C; Taylor JC; ; Eyre S; Churchman SM; Wilson AG; Isaacs JD; Hyrich K; Barton A; Plant D; Savic S; Cook GP; Sarzi-Puttini P; Emery P; Barrett JH; Morgan AW; McDermott MF
Ann Rheum Dis; 2014 Jun; 73(6):1202-10. PubMed ID: 23687262
[TBL] [Abstract][Full Text] [Related]
9. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment.
Tan RJ; Gibbons LJ; Potter C; Hyrich KL; Morgan AW; Wilson AG; Isaacs JD; ; Barton A
Ann Rheum Dis; 2010 Jun; 69(6):1029-35. PubMed ID: 20444755
[TBL] [Abstract][Full Text] [Related]
10. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
11. Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
Suarez-Gestal M; Perez-Pampin E; Calaza M; Gomez-Reino JJ; Gonzalez A
Arthritis Res Ther; 2010; 12(2):R72. PubMed ID: 20423481
[TBL] [Abstract][Full Text] [Related]
12. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
[TBL] [Abstract][Full Text] [Related]
13. Lack of association of variants previously associated with anti-TNF medication response in rheumatoid arthritis patients: results from a homogeneous Greek population.
Zervou MI; Myrthianou E; Flouri I; Plant D; Chlouverakis G; Castro-Giner F; Rapsomaniki P; Barton A; Boumpas DT; Sidiropoulos P; Goulielmos GN
PLoS One; 2013; 8(9):e74375. PubMed ID: 24040234
[TBL] [Abstract][Full Text] [Related]
14. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy.
Cui J; Saevarsdottir S; Thomson B; Padyukov L; van der Helm-van Mil AH; Nititham J; Hughes LB; de Vries N; Raychaudhuri S; Alfredsson L; Askling J; Wedrén S; Ding B; Guiducci C; Wolbink GJ; Crusius JB; van der Horst-Bruinsma IE; Herenius M; Weinblatt ME; Shadick NA; Worthington J; Batliwalla F; Kern M; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Seldin MF; Moreland LW; Behrens TW; Allaart CF; Criswell LA; Huizinga TW; Tak PP; Bridges SL; Toes RE; Barton A; Klareskog L; Gregersen PK; Karlson EW; Plenge RM
Arthritis Rheum; 2010 Jul; 62(7):1849-61. PubMed ID: 20309874
[TBL] [Abstract][Full Text] [Related]
15. A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility.
Marinou I; Walters K; Winfield J; Bax DE; Wilson AG
Ann Rheum Dis; 2010 Jun; 69(6):1191-4. PubMed ID: 19713205
[TBL] [Abstract][Full Text] [Related]
16. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
[TBL] [Abstract][Full Text] [Related]
17. A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
Aterido A; Cañete JD; Tornero J; Blanco F; Fernández-Gutierrez B; Pérez C; Alperi-López M; Olivè A; Corominas H; Martínez-Taboada V; González I; Fernández-Nebro A; Erra A; López-Lasanta M; López Corbeto M; Palau N; Marsal S; Julià A
Front Immunol; 2019; 10():1459. PubMed ID: 31312201
[No Abstract] [Full Text] [Related]
18. Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis.
Lamas JR; Rodríguez-Rodríguez L; Tornero-Esteban P; Villafuertes E; Hoyas J; Abasolo L; Varadé J; Alvarez-Lafuente R; Urcelay E; Fernández-Gutiérrez B
Cytokine; 2013 Mar; 61(3):720-3. PubMed ID: 23375120
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis.
Honne K; Hallgrímsdóttir I; Wu C; Sebro R; Jewell NP; Sakurai T; Iwamoto M; Minota S; Jawaheer D
Arthritis Res Ther; 2016 Jan; 18():12. PubMed ID: 26776603
[TBL] [Abstract][Full Text] [Related]
20. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
